This piece gets in on big-money merit. Check out the Wall Street Journal for a quick story about Novartis and MorphoSys, a German biotech, expanding their collaboration -- to the tune of a 10-year, $600 million partnership. The alliance is geared toward "the discovery and development of antibody-based biological drugs," according to the article.

 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.